We have previously isolated a cDNA encoding a human uracil-DNA glycosylase which is closely related to the bacterial and yeast enzymes. In vitro expression of this cDNA produced a protein with an apparent molecular weight of 34 K In agreement with the size predicted from the sequence data. The In vitro expressed protein exhibited uracil-DNA glycosylase activity. The close resemblance between the human and the bacterial enzyme raised the possibility that the human enzyme may be able to complement E. coll ung mutants. In order to test this hypothesis, the human uracil-DNA glycosylase cDNA was established In a bacterial expression vector. Expression of the human enzyme as a LacZa-humUNG fusion protein was then studied in E. coll ung mutants. E. coll cells lacking uracil-DNA glycosylase activity exhibit a weak mutator phenotype and they are permissive for growth of phages with uracil-containing DNA. Here we show that the expression of human uracil-DNA glycosylase in E. coll can restore the wild type phenotype of ung mutants. These results demonstrate that the evolutionary conservation of the uracil-DNA glycosylase structure is also reflected in the conservation of the mechanism for removal of uracil from DNA.
INTRODUCTION
Spontaneous deamination of bases in DNA occurs at a considerable rate in living cells and may give rise to transition mutations (1, 2). Cytosine and 5-methylcytosine deaminate to uracil and thy mine respectively, resulting in U:G and T:G mispairs. Adenine deaminates to hypoxanthine resulting in an H:T basepair (usually referred to as an inosine:thymine basepair). Prokaryotic and eukaryotic organisms possess base specific DNA repair enzymes like uracil-, thymine-and hypoxanthine-DNA glycosylases. These enzymes can counteract the mutagenic effect of base deaminations by removing the deamination product and thereby initiating the base excision repair pathway (3, 4) . Uracil-DNA glycosylase will also remove uracil from A:U basepairs and acts on both double and single stranded DNA (5) .
A group of related genes encoding uracil-DNA glycosylases has recently been described with members in several species including bacteria, yeast, man as well as the herpes viruses (6) (7) (8) (9) (10) (11) (12) . In addition to the human uracil-DNA glycosylase cDNA (UNG15/4O\) isolated by us, two other human cDNAs encoding uracil-DNA glycosylases have been reported and they are apparently unrelated to this gene family as well as to each other (13, 14) . The gene encoding the latter cDNA is located on chromosome 5 (14) , while the gene encoding UNG15/40 has been assigned to chromosome 12 (15) . Intriguingly, the cDNA isolated by Muller and Caradonna shows considerable sequence similarity to the conserved region of the cyclin gene family.
Mitochondria have been reported to contain a uracil-DNA glycosylase (16) (17) (18) . Whether the nuclear and the mitochondrial forms of uracil-DNA glycosylase are structurally related is not known. We have recently found evidence suggesting that the UNG15/40 gene encodes a nuclear enzyme (G. Slupphaug, L.C.O., R.A., D.E.H., and H.E.K., submitted). The mitochondrial enzyme may derive from one of the other genes mentioned above or from a different gene. As an alternative, we have proposed that the nuclear and mitochondrial form may both arise from the UNG15/40 gene (9) .
Among the characterized members of the uracil-DNA glycosylase family, the human uracil-DNA glycosylase is most similar to the E. coli Ung protein showing 55.7% sequence identity. A functional similarity is also supported by the fact that the PBS2 encoded uracil-DNA glycosylase inhibitor protein (JJgi) is capable of blocking the activity of both the bacterial and the human uracil-DNA glycosylases by binding to the enzyme (19, 20) . However, Ugi does not inhibit other DNA glycosylases (19) . These observations raised the question that human uracil-DNA glycosylase might be able to function in E. coli.
We decided to test this possibility by examining whether human uracil-DNA glycosylase can complement strains of E. coli deficient in this enzyme. Complementation of E. coli DNA repair Note: The human gene from which the UNG 15 and UNG40 cDNA clones derive has been assigned the name DGU (15) but in order to explicitly refer to this gene, we use the term UNG15/40 throughout this paper. mutants tagAJalkA and ada was recently successfully used to isolate the corresponding mammalian DNA repair genes encoding 3-methyladenine-DNA glycosylase and C^-methylguanine-DNA methyltransferase (21, 22) . We have taken advantage of the fact that E. coli ung mutants show a weak mutator phenotype and are permissive for growth of phages with uracil-containing DNA (23) (24) (25) . By expressing the human uracil-DNA glycosylase in an E. coli ung mutant, we here show that the human gene is capable of complementing the u/ig-mutation. (26) . Nick-translation of calf thymus DNA in the presence of [S'^HJdUTP (Amersham) at a specific activity of 0.5 Ci/mmol was carried out as described by Krokan and Wittwer (27 Figure 1 ], and 8,000 cpm when using the PCR generated substrate [ Figure 4 ]). Sonicated salmon sperm DNA was added as a coprecipitant to a final concentration of 0.72 /xg//xl and the DNA precipitated by adding 500 /xl ice cold 5% TCA. After centrifugation for 10 minutes at 12,000 g the amount of acid-soluble radioactive material was measured using a liquid scintillation counter.
MATERIAL AND METHODS

Bacteria
Paper chromatography
The reaction mixture from the uracil-DNA glycosylase assay, was heat inactivated for 2 minutes at 100°C and applied to GB 002 paper (Schleicher & Schuell) and developed with isobutyric acid, ddH 2 O, 0.1 M EDTA, concentrated ammonia, toluene (160:22:3:2:20 by volume) as previously described (28) . The chromatogram was then cut into 2 cm pieces, and the radioactivity of each fraction determined. dUTP, uridine and uracil (all from Sigma) were included as markers.
In vitro transcription/translation
The plasmids pUNG15 and pUNG40 were linearized (at the 3'-end of the cDNA-insert relative to the T7 or SP6 promoter being used) by treatment with an appropriate restriction endonuclease. Standard in vitro transcription assays were performed in a final volume of 100 (i\ containing 2-5 tig template DNA. Synthesis of sense and antisense RNA was carried out at 37 °C for 1 hour using either T7 or SP6 RNA polymerase (Promega) in accordance with the manufacturer's protocol. Capped transcripts were synthesized by including m 7 G(5')ppp5'G (Pharmacia) at 0.5 /xM. Ribonucleotides were present at 0.5 yM except for rGTP which was present at a concentration of 0.05 /xM. The DNA template was removed by adding RNase free DNasel (Pharmacia) and the incubation was continued at 37°C for 15 minutes. The in vitro synthesized RNA was extracted once with phenol-chloroform (1:1) and once with chloroform and ethanol precipitated.
In vitro translation of the in vitro synthesized RNA was carried out at 30°C for 30 minutes in the presence or absence of [ After incubation, the translation products were precipitated with acetone, resolved in 100 ill SDS-sample buffer. Aliquots of 25 ill were electrophoretically separated on a 12.5% SDSpolyacrylamide gel (29) . [ l4 C]Methylated proteins (Amersham) were used as molecular weight markers. The gel was dried and autoradiographed. Unlabelled proteins were tested for uracil-DNA glycosylase activity.
Construction of uracil-DNA glycosylase expression plasmid
The plasmid pG7bUNG was constructed by inserting the 1775bp BamKL-EcoKl fragment of pUNG15 (nucleotide position 297 to 2071; position no. 1 is the first nucleotide of the cDNA insert in pUNG15) into BamW and £coRI digested pGEM-7Zf(+) (Promega), generating a JacZa-humUNG fusion gene ( Figure 3) . A correct junction between lacZ and humUNG was confirmed by DNA sequencing.
Transformation
Transformation of competent bacteria with 1 ng DNA was performed by electroporation (30) using a Bio-Rad GenePulser at 25 tiF, 2.5 kV and the pulse controller set to 200 ohms.
Induction of LocZa-humUNG fusion protein and preparation of cell extracts
Overnight cultures of E. coli cells were diluted 1:100 with LB medium (50 ml final volume) supplemented with ampicillin when appropriate and grown at 37°C for 2 hours. IPTG (isopropyl-0-thiogalactopyranoside; Sigma) was added to a final concentration of 1 mM to cultures of NR8052/pG7bUNG cells and incubated for an additional 2 hours. The cells were harvested by centrifugation at 4,500 g for 15 minutes at 4°C. The pellets were resuspended in 5 ml 50 mM Tris-HCl pH 8.0, 1 mM EDTA and disrupted by sonication (5 pulses of 30 seconds) using an Ultrasonic instrument at 30 fiA. Cell debris was removed by centrifugation at 12,000 g for 15 minutes at 4°C. The supernatant was diluted 1:50 in 50 mM Tris-HCl pH 8.0, 1 mM EDTA and aliquots of 2, 5, and 12 /J were assayed for uracil-DNA glycosylase activity.
Plaque assay
Passages of \vir through either E. coli NR8051 or CJ236 were performed to generate thymine containing (Xw'r[T]) and uracilcontaining phages (\vir[U]), respectively. The ability of these two types of phages to grow on different bacterial strains was then tested.
Mutator assay
-, To detect the number of rifampicin resistant bacteria 1 ml of the appropriate bacterial culture was mixed with 3 ml top agarose and poured on LB-plates containing 50 /xg/ml rifampicin (Sigma) and incubated overnight at 37°C. The colonies were counted and the number of rifampicin resistant colonies per 10 8 viable cells was calculated. In the mutator assay we have estimated the smallest lethal dose of rifampicin to be 50 /tg/ml.
RESULTS
In vitro expression of human uracil-DNA glycosylase cDNA clones
In vitro expression analysis of two human placental cDNA clones (9) were performed and the translation products tested for enzyme activity. Uracil-DNA glycosylase activity was easily detected after in vitro transcription/translation of the UNG15 cDNA (Figure 1 ). This result demonstrates that this cDNA clone encodes a functional uracil-DNA glycosylase. In vitro transcription/ translation of the shorter cDNA clone, UNG40, did not give rise to any functional protein, probably due to the lack of an appropriate in-frame methionine codon. No uracil-DNA glycosylase activity was detected in the rabbit reticulocyte lysate itself (data not shown). Neither was any enzyme activity detected upon translation of UNG 15 antisense RNA.
The molecular weight of the uracil-DNA glycosylase which was purified from human placenta was estimated to be 29 K (31). The N-terminal amino acid sequence of this enzyme was the basis for the isolation of UNG40 and UNG15 cDNAs. The open reading frame of the UNG15 cDNA clone has a coding capacity for a protein of molecular weight of 33.8 K (9). Radiolabelled in vitro translation-products were analyzed by SDS-PAGE and visualized by autoradiography. A polypeptide with an apparent molecular weight of 34 K was observed in agreement with the size estimated from the sequence data ( Figure 2 ).
Expression of human uracil-DNA glycosylase cDNA in E. coli
The strong amino acid sequence similarity between the human and bacterial uracil-DNA glycosylases suggests that the human uracil-DNA glycosylase cDNA may complement the ung mutation in E. coli. To test this hypothesis, the expression vector pG7bUNG was constructed, where the 63 N-terminal codons of the UNG-reading frame were replaced with the 26 N-terminal codons of the ZacZ-reading frame of pGEM-7Zf( + ) (Figure 3 ). This LacZa-humUNG fusion protein lacks most of the putative presequence of the human uracil-DNA glycosylase (9) . The /acZa-humUNG fusion gene is under the control of the inducible foe-promoter. The ung~ bacterial strain NR8052 was then transformed with this plasmid.
Lysates of NR8052 and NR8052/pG7bUNG as well as the isogenic ung + strain, NR8051, were tested for uracil-DNA glycosylase activity (Figure 4) . The enzyme activity of NR8O52/pG7bUNG was similar to that of the wild type strain NR8051, while the ung mutant strain NR8052 showed less that 1% of the activity of the wild type strain. These results demonstrate that the human uracil-DNA glycosylase is expressed as a functional enzyme in E. coli. Extracts from a NR8052 strain carrying vector without insert, pGEM-7Zf( + ), did not reveal any detectable uracil-DNA glycosylase. Treatment of NR8052/pG7bUNG with the foc-inducer IPTG did not consistently result in higher levels of enzyme activity as compared to untreated cells. The expression of the LacZa-humUNG fiasion protein in the absence of inducer is probably due to the titration of the foc-repressor as a result of the high copy number of plasmids in these cells. An inhibition of the enzyme apparently occurs when the largest amounts of bacterial extracts were assayed ( Figure 4 ; NR8051 and NR8O51/pG7bUNG +IPTG).
Released tritiated material from DNA incubated with cell extracts of NR8052/pG7bUNG comigrated with uracil in paper chromatography. Cell extracts from the ung~ strain did not release any detectable material comigrating with uracil (data not shown). These results show that the liberated tritiated products in the standard enzyme assay resulted from a uracil-DNA glycosylase activity and not from unspecific nucleases.
Human uracil-DNA glycosylase is able to remove uracil from U:A basepairs in E. coli The presence of an active human uracil-DNA glycosylase in lysates of NR8052/pG7bUNG does not imply that the human enzyme is capable of complementing E. coli ung mutants in vivo. Two different biological assays have been used to examine if the human uracil-DNA glycosylase gene product may restore the wild-type phenotype of E. coli ung mutant cells. These assays are based on the facts that E. coli ung mutants exhibit a weak mutator phenotype (23) as well as being permissive for phages with uracil-containing DNA (24, 25) .
Uracil-containing phages were prepared by passing Xvir through an E. coli dut ung strain where as much as 30% of the thymine content may be replaced by uracil (32) . These Xvir[U] phages are severely restricted in their ability to multiply in uracil-DNA glycosylase expressing bacteria since the phage DNA is degraded by the combined action of the glycosylase and APendonucleases. The phage assay measures the ability of the human enzyme to remove uracil from an A:U basepair.
The ability of Xvir[U] to grow on NR8O52/pG7bUNG was reduced with a factor of about 350 as compared to NR8052 (Figure 5 ), indicating that Xvir[U] is fragmented into smaller pieces due to an active human uracil-DNA glycosylase working together with AP endonucleases. The titer of Xvir[U] grown on uninduced NR8052/pG7bUNG was 16 fold higher as compared to the induced NR8052/pG7bUNG. This indicates that IPTG has a positive effect on the expression of the LacZa-humUNG fusion protein under these conditions. No difference in the plating efficiency of Xvir[U] on NR8052/pGEM-7Zf( + ) compared to NR8052 was seen ( Figure 5 ). The titer of Xvir[U] on NR8052/pG7bUNG was 30 fold higher as compared to the wildtype cells, suggesting that there is a difference in the ability of the human enzyme to remove U in an A:U basepair as compared to the bacteria] enzyme. Longterm storage of NR8052/pG7bUNG resulted in bacteria that were more permissive for growth of Xvir[U] as compared to cells that have been transformed with pG7bUNG immediately before running the phage assay. This may be due loss or alteration of the plasmid during storage.
Human uracil-DNA glycosylase is able to remove uracil from U:G mismatches in E. coli Spontaneous mutation to rifampicin resistance due to C:G-T:A transition mutations in the rpoB gene has been reported to be about 5-fold higher in ung mutants then in wild type cells (23) . Different E. coli strains were grown on LB-plates containing rifampicin and the number of resistant colonies scored. The frequency of spontaneous mutation to rifampicin resistance was 2.4 fold higher in NR8052 ung~ cells as compared to wild-type cells ( Figure 6 ). The rifampicin mutator assay also showed that uninduced NR8052/pG7bUNG cells gave virtually the same number of revertants, 11.3 rifampicin resistant bacteria/10 8 viable cells, as wild type cells ( Figure 6 ). When NR8052/pG7bUNG cells were grown in the presence of both EPTG and rifampicin, the number of revertants was reduced 1.8 fold as compared with uninduced NR8052/pG7bUNG cells and wild type cells. These results clearly indicate that expression of the human uracil-DNA glycosylase in E. coli ung mutants suppresses the weak mutator phenotype of these cells.
DISCUSSION
In this report, we have shown that a human uracil-DNA glycosylase cDNA gave rise to an active gene product both after in vitro expression and by expression in E. coli ung mutant cells. The molecular weight of the in vitro expressed human uracil-DNA glycosylase was found to be 34 K in agreement with the molecular weight estimated from the open reading frame of the UNG 15 cDNA. However, the molecular weight of the purified protein from human placenta was reported to be 29 K (31) and the reported N-terminal amino acid sequence of this protein is situated at position 78-105 in the predicted sequence of the UNG15 encoded protein (9) . Based on this observation we suggested that the human uracil-DNA glycosylase may be processed in vivo (9) . Alternatively, the smaller size of the purified human placental uracil-DNA glycosylase may be a result of artificial cleavage during the purification procedure. A similar situation is found in yeast, where the purified uracil-DNA glycosylase is smaller than predicted from sequence data (8) .
The 34 K protein expressed from the UNG 15 cDNA in vitro is similar in size to the 33-37 K mammalian uracil-DNA glycosylases previously reported (33) (34) (35) . However, the apparent structural differences between UNG 15 and the cDNAs described by Vollberg et al., (13) and Muller and Caradonna (14) indicates that the encoded proteins are different.
We have earlier reported that uracil-DNA glycosylases from different species including man and E. coli are highly conserved (9) . This observation suggested that the human uracil-DNA glycosylase gene may complement E. coli ung deficient cells. Here we have shown that expression of the human protein as a LacZa-humUNG fusion protein in E. coli ung~ cells almost completely restored the wildtype phenotype of these mutant cells. The activity of the LacZa-humUNG fusion protein in the bacteria depends on the efficiency of transcription and translation, as well as the catalytic efficiency of the enzyme in the bacteria. Since we have not examined these aspects of expression of human uracil-DNA glycosylase in E. coli, we cannot conclude from our present data that the human and the bacterial enzymes have comparable specific activities in the bacteria.
The phage assay and the mutator assay clearly demonstrated that the human enzyme when expressed in E. coli, is capable of removing uracil from both U:A and U:G basepairs. These data indicates that the repair mechanism involved in the removal of uracil from DNA in E. coli and human cells are quite similar. However, it should be noted that the complementation appears complete in the mutator assay ( Figure 6 ) while only partial complementation was observed with the phage assay ( Figure 5 ). This result can be explained by the fact that the 26 N-terminal amino acids corresponding to the LacZa-peptide of the fusion protein may disturb the catalytic efficiency of the fusion protein or may indicate that the human enzyme has a different specificity towards U:G and U:A basepairs as compared with the E. coli enzyme. Alternatively, these observations may be explained by the anticipated presence of a high concentration of uracil in the phage DNA as compared to a much lower concentration of uracil in the chromosomal DNA due to cytosine deamination in the mutator assay.
The mammalian DNA repair enzymes 3-methyladenine-DNA glycosylase and C^-methylguanine-DNA methyltransferase have recently been cloned by phenotypic rescue of DNA repairdeficient E. coli mutants (21, 22) . These results together with our complementation data indicate that elements of several DNA repair pathways are evolutionarily conserved between prokaryotes and mammals. These data further suggest that other eukaryotic DNA repair genes may be isolated by phenotypic rescue of E. coli mutants. A partial complementation has indeed been observed by expression of the rat DNA polymerase jS in E. coli polA mutants (36) . Using complementation as a strategy for isolation of DNA repair genes is also encouraged by the recent success in the isolation of a series of mammalian genes by complementation of mammalian cells which are deficient in DNA repair (37) . In experiments using monoclonal antibodies, Seal and Sirover (38) found that uracil-DNA glycosylase and DNA polymerase a may be physically associated. It has thus been speculated that uracil-DNA glycosylase may be organized in a multiprotein DNA repair complex. If uracil-DNA glycosylase must be part of a multiprotein complex in order to be fully functional, one would expect that complementation of E. coli ung~ cells by addition of only the human UNG gene would not occur since the human uracil-DNA glycosylase would probably be unable to recognize other bacterial proteins involved in such a multiprotein complex. Relevant to these considerations is the recent report that DNA polymerase & cannot be replaced by the phage T4 DNA polymerase alone in an in vitro SV40 replication assay. However, the DNA polymerase 6 with its accessory proteins (PCNA and replication factor Q can be substituted by an analogous complex of phage T4 proteins (39) .
The phage and the mutator assays used here represent excellent tools for evaluating mutant forms of the human uracil-DNA glycosylase enzyme in E. coli ung~ cells and will therefore be an important tool in the identification of the functional domains of this enzyme.
